Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Cell Depleted Allo-HSCT with DLI for Multiple Myeloma
NCT01131169Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2010
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of busulfan, melphalan, fludarabine and antithymocyte globulin rabbit in multiple myeloma (MM) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started May 2010; status: completed.
02
Drugs
busulfanmelphalanfludarabineantithymocyte globulin rabbit
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01131169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131169.